Minnesota-based AMS is a diversified supplier of medical devices and procedures to treat incontinence, erectile dysfunction, benign prostatic hyperplasia (BPH), pelvic floor prolapse and other pelvic disorders in men and women.

These include a broad range of products for erectile dysfunction prostheses and male and female incontinence, as well as GreenLight laser technology for enlarged prostate treatment.

AMS also has a pipeline of new products that are expected to boost the commercial portfolio and growth trajectory over the next few years.

This anticipated growth, combined with strong margins and solid free cash flow generation, makes AMS a compelling strategic fit for Endo.

Endo president and CEO Dave Holveck said through the acquisition of AMS, they will gain scale in devices and services, and will be positioned as a leading provider of healthcare solutions in the field of pelvic health, with a full spectrum of product offerings ranging from pharmaceuticals to medical devices.